Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 2
1963 1
1964 2
1965 1
1966 3
1967 3
1968 4
1970 4
1971 7
1972 2
1973 2
1974 3
1975 2
1976 2
1977 10
1978 10
1979 7
1980 11
1981 15
1982 18
1983 23
1984 29
1985 23
1986 29
1987 44
1988 50
1989 47
1990 43
1991 52
1992 56
1993 75
1994 69
1995 75
1996 96
1997 126
1998 147
1999 225
2000 275
2001 281
2002 335
2003 357
2004 439
2005 482
2006 563
2007 648
2008 713
2009 828
2010 985
2011 1252
2012 1363
2013 1411
2014 1490
2015 1612
2016 1502
2017 1594
2018 1604
2019 1673
2020 1893
2021 1982
2022 757
Text availability
Article attribute
Article type
Publication date

Search Results

22,592 results
Results by year
Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. Among authors: park yh. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Schmid P, et al. Among authors: park yh. N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651. N Engl J Med. 2022. PMID: 35139274 Clinical Trial.
Super enhancers define regulatory subtypes and cell identity in neuroblastoma.
Gartlgruber M, Sharma AK, Quintero A, Dreidax D, Jansky S, Park YG, Kreth S, Meder J, Doncevic D, Saary P, Toprak UH, Ishaque N, Afanasyeva E, Wecht E, Koster J, Versteeg R, Grünewald TGP, Jones DTW, Pfister SM, Henrich KO, van Nes J, Herrmann C, Westermann F. Gartlgruber M, et al. Among authors: park yg. Nat Cancer. 2021 Jan;2(1):114-128. doi: 10.1038/s43018-020-00145-w. Epub 2020 Dec 7. Nat Cancer. 2021. PMID: 35121888
Targeting mutations in cancer.
Waarts MR, Stonestrom AJ, Park YC, Levine RL. Waarts MR, et al. Among authors: park yc. J Clin Invest. 2022 Apr 15;132(8):e154943. doi: 10.1172/JCI154943. J Clin Invest. 2022. PMID: 35426374 Free PMC article. Review.
Artist's Statement: COVID-19 mRNA Vaccines.
Park YJ. Park YJ. Acad Med. 2022 May 1;97(5):634. doi: 10.1097/ACM.0000000000004626. Epub 2022 Apr 27. Acad Med. 2022. PMID: 35476836 Free PMC article. No abstract available.
Ultrasonographic atlas of splenic lesions.
Choi G, Kim KA, Lee J, Park YS, Lee J, Choi JW, Lee CH. Choi G, et al. Among authors: park ys. Ultrasonography. 2022 Apr;41(2):416-429. doi: 10.14366/usg.21189. Epub 2021 Dec 2. Ultrasonography. 2022. PMID: 35045593 Free PMC article.
22,592 results
You have reached the last available page of results. Please see the User Guide for more information.